Background. High rates of endemic disease and recurrent epidemics of serogroup A and C meningococcal meningitis continue to occur in sub-Saharan Africa. A meningococcal A + C polysaccharide diphtheria-toxoid-conjugated vaccine may address this issue.
INTRODUCTION
In Niger, which lies within the "meningitis belt" of sub-Saharan Africa," Neisseria meningitidis causes an annual average between epidemics of 30 cases of meningitis per 100 O00 population; 85% of meningococcal cases are caused by serogroup A strains, with the remaining cases predominantly caused by serogroup C meningoc~cci.~ Although meningococcal polysaccharide vaccine is currently used to control serogroup A and C epidemics in Niger, even if the epidemic is detected early, vaccination is nearly always started too late t o prevent most cases. Conjugation of polysaccharide antigens to protein carriers could potentially overcome the poor immunogenicity of polysaccharide vaccines in infancy by converting a T cell-independent response to a T cell-dependent one and result in efficacious conjugate vaccines that could be incorporated into the Expanded Program of Immunization (EPI).
This study determined the immunogenicity and safety in infants from Niamey, Niger of three formulations (containing 1, 4 or 16 pg of both polysaccharides per dose) of N. meningitidis A + C-diphtheria toxoidconjugated vaccine (MenD) in comparison with two controls: a meningococcal A -k C polysaccharide vaccine (MenPS) and a Haemophilus influenzae type b-tetanus toxoid-conjugated vaccine (PRP-T). The anamnestic response was assessed 8 months after primary immunization by vaccination with a single dose of MenPS at 11 to 12 months of age in the children already immunized with MenD or MenPS. This study followed preliminary studies conducted in adults, toddlers and infants in the US to evaluate the safety and immunogenicity of the same three formulations of MenD. 144
METHODS
The study was conducted between January, 1996, and March, 1997, at Yantala Centre de Santé Maternelle et Infantile in Niamey, Niger. The parents of the infants gave their written consent before inclusion, after being informed about the nature of the trial and any potential risks. If neither parent could read or write, two witnesses had to attest, by signing the consent form, that the parents had been properly informed about the protocol and had agreed to their child's inclusion. Free medical care was provided to the infants during the course of the study. The Subjects. Healthy children of either sex between 5 and 9 weeks of age were recruited for the study on presentation for routine EPI administration of the first diphtheria and tetanus toxoid-whole cell pertussis (DTP) vaccine.
Vaccines. The study vaccine was a polysaccharideprotein conjugate vaccine manufactured by Aventis Pasteur (Swiftwater, PA) prepared with serogroup A and C meningococcal polysaccharides, each covalently bound to diphtheria toxoid (MenD). Three vaccine lots were prepared (Lots 950213,950214 and 950215) that contained, respectively, per 0.5-ml dose, 1 , 4 or 16 pg of each polysaccharide and 5.8, 32.2 or 161.0 pg of diphtheria toxoid. The investigational vaccine was presented in a prefilled (0.5-ml) ready to use glass syringe.
Infants in the control groups received either meningococcal polysaccharide A + C vaccine (MenPS, Vaccin Polyosidique Meningococcique A + C, Batches LO878
and LO991, containing 50 pg of group A and 50 pg of group C meningococcal polysaccharides) or one 0.5-ml dose of H. infZuen2a.e type b conjugate vaccine (PRP-T, Act-HIB, Batch L0670), both manufactured by Aventis Pasteur (Lyon, France). The placebo was 0.5 ml of a 0.4% normal saline solution. The study vaccine or control vaccines were administered intramuscularly in the anterolateral aspect of the right thigh. Infants recruited into the study already had received Calmette-Guérin bacillus and oral polio vaccine at birth according to Niger's EPI schedule. At the ages of 6, 10 and 14 weeks, they received DTP vaccine subcutaneously in the left deltoid region and oral polio vaccine. At 9 months of age measles and yellow fever vaccines were administered. All vaccines were obtained from EPI-approved vaccine manufacturers.
Study design. This was a randomized dose escalation study. A total of 180 children were randomly allocated to 1 of 5 groups ( Table 1 ). The 108 infants allocated to the MenD group received 1 of the 3 formulations of the meningococcal conjugate vaccine at 6, 10 and 14 weeks of age. Dose escalation was sequential. A first subgroup of 36 infants received the 1-pg polysaccharide dose; if no reactogenicity was observed exceeding that commonly expected for DTP vaccine, then a second group of 36 infants received the 4-pg polysaccharide dose; a third group of 36 infants received the 16-pg polysaccharide dose. Two other groups of infants in this joint randomization, -36 subjects each, enrolled as 3 series of 12 subjects, served as controls at each step. In the preceding year, 1995, a massive serogroup A meningococcal outbreak in Niger had caused more than 40 O00 reported cases: so the study was designed such that all participating infants would be offered a meningococcal vaccine by the end of the study. Thus one control group received the MenPS vaccine (1 dose of saline placebo at 6 weeks and 2 doses of MenPS at 10 and 14 weeks of age), and the other group, the PRP-T vaccine control group (3'doses at 6,lO and 14 weeks of age), received a dose of meningococcal A + C polysaccharide vaccine at 18 weeks of age, after participation in the initial study was complete. To evaluate the impact of MenD vaccine on memory priming, as compared with the plain polysaccharide vaccine, an amendment to this study was proposed in December, 1996, such that all infants of the MenD and MenPS groups received one dose of MenPS vaccine between 11 and 12 months of age. (Infants of the PRP-T control group were not tested for memory priming.)
Two blood samples were collected by venipuncture from each infant at 6 and 18 weeks of age. For infants in the MenD and MenPS groups included in the study amendment, two additional blood samples were collected, one before the MenPS vaccination dose at 11 months of age and one 4 weeks later.
The parents, the home visitors who assessed local and systemic reactions and the laboratory personnel were blinded to the subjects' study groups.
Reactogenicity. Infants in the study were observed in the clinic for 15 min after each vaccination for \ immediate reactions. During the dose escalation stage of this study, local and systemic reactions were monitored by home visitors during each of the 5 days after each injection; after MenPS vaccination at 11 months of age, local and systemic events were monitored at 24 and 72 h after injection, respectively. Laboratory methods. Meningococcal A and C polysaccharide total antibody concentrations (measured as IgG) were determined for all serum samples using a standardized enzyme-linked immunosorbent assay (ELISA) at Aventis Pasteur (US) and expressed as micr~grams/ml.~' Serum bactericidal activity (SBA) was measured for all specimens at the Centers for Disease Control and Prevention Laboratory (Atlanta, GA) by adding group-specific meningococcal bacteria in the presence of baby rabbit origin complement to serial dilutions of a serum ample.^ Bactericidal activity was defined as the reciprocal serum dilution yielding 150% killing as compared with the controls. Seroprotection levels were defined as the percentage of subjects with postimmunization ELISA antibody concentrations 2 2 pg/ml and reciprocal SBA titers 28.82 Data analysis. Safety data were described for each group and each vaccine dose by the percentage of infants with at least one local or systemic reaction. Geometric mean titer (GMT) values of ELISA antibody concentrations and SBA activities, as well as the seroprotection rates, were calculated with their 95% confidence intervals. Groups were compared by analysis of covariance, including the loglo-transformed 18-week baseline titer as the dependent variable, the log,,-transformed 6-week baseline titer as the independent factor and the group-by-baseline interaction as the covariate. As a result of multiple endpoints (i.e. two serogroups) and multiple comparisons, statistical significance was declared for the global comparison at an alpha risk of 0.025 (two-sided) and of the linear contrasts at an alpha risk of 0.00625 (two-sided). Statistical analysis was carried out by the Aventis Pasteur Biometry Department (Lyon, France) on SAS Version 6.08 (SAS Inc., Cary, NC)
RESULTS
A total of 180 infants were enrolled; the male-tofemale ratio was 0.97 and the mean age at inclusion was 44.8 -+ 5.8 days, with no difference between the study groups for either characteristic. Eight months later 116 infants were recontacted and included in the 11-month MenPS vaccination.
Local and systemic reactions after primary series. No child suffered an immediate reaction during the 15 min after any injection. The most frequently observed local reactions were tenderness and redness at the site of injection (Table 21 , which were mild and short lived. The cumulative frequency of tenderness after three injections at the injection site in the three MenD groups combined was 37.6%; for MenPS, it was 30.8%, and for PRP-T, 19.6%. The cumulative frequency of redness after three injections was 18.1% for children in the three MenD groups, 7.5% for MenPS recipients and 11.2% for PRP-T recipients. There was no increase in the incidence of local reactions with subsequent injections during the primary immunization series.
The systemic reactions in the MenD 16-pg vaccine group, rangingfrom 38.9 to 57.1%, appeared to be more frequent than with either one of the lower doses, which were never more than 37% (Table 2 ). The rates of systemic reactions during the primary immunization series also did not increase with successive injections in any group.
Local and systemic reactions after MenPS vaccination of the 11-month-old-children. The reactogenicity profile after the MenPS vaccination a t 11 months of age in infants who had previously received the MenD vaccine was similar to that observed ( Table  2) during the primary series. There appeared to be, once again, a more pronounced local reactogenicity observed among the infants receiving MenD at the lower doses as compared with the MenD 16-pg group. This was particularly noteworthy for local tenderness (Data not shown).
Serions adverse events. Eight serious adverse events requiring hospitalization were reported during the trial, all of which were considered by the investigator either to be unrelated to or have an improbable relationship with the study vaccine. In the 1-pg MenD group, there was one case of diarrhea and dehydration associated with fever, and one infant in the MenPS group developed an intercurrent infection and severe dehydration; both led to the death of the child. For all other events, by the end of documented study followup, the infant had at least recovered partially. Immunogenicity: antibody response measured
by ELISA. Table 3 shows the immune response expressed in terms of GMT values of antibody measured by ELISA. (In the text that follows, the proportion of n antibody titer 2 2 pg/ml is given For serogroup A, the post-Dose 3 immune responses by ELISA observed with the MenD vaccine were 4.6 pg/ml(88.6%), 5.8 pg/ml(88.2%) and 9.9 pg/ml(96.9%) for the 1-, 4-and 16-pg vaccine doses, respectively. There was a significant difference in dose effect between the 16-1.1.8 and the l-pg dose (P = 0.0002). For serogroup C the post-Dose 3 ELISA immune responses measured with the MenD vaccine were 1.5 pg/ml (34.0%), 2.8 pg/ml (64.5%) and 4.8 Fg/ml (87.5%), respectively, for the three dose levels. The MenPS vaccine induced comparable ELISA results for serogroups A, 5.5 pg/ml (87.9%), and C, 5.3 pdml (81.8%). M e r the 11-month MenPS vaccination we observed serum antibody titers 2 2 pg/ml in 91.7,83.3 and 69.2% against serogroup A and 83.3, 83.3 and 92.3% against serogroup C, for the 1-, 4-and 16-pg MenD dose groups, * respectively. The same proportion of infants in the MenPS group (58.6%) had seroprotective levels against serogroups A and C after this 11-month MenPS vaccination. Immunogenicity: SBA. Table 4 shows the SBA expressed as GMTs, the reciprocal of the dilution. (In the following text the proportion of infants achieving reciprocal titers 2 8 and the P value of the 95% confidence intervals (CIS) comparison are given in parentheses.)
For serogroup A the post-Dose 3 immune responses observed with the MenD vaccine were 261 (97.1%), 171 (94%) and 370 (100%) for the three levels of doses, with no statistically significant difference between them. In contrast the SBA values in the MenPS and the PRP-T groups were 7.0 (31%) and 6.7 (18.9%), respectively, each significantly less than for the MenD groups: P = 0.0001 (P 5 0.05 when comparing the 95% CIS). For serogroup C the SBA values were 72.1 (94.3%), 189 (100%) and 325 (100%) for the three doses, with a statistically significant dose effect: P = 0.0001. The SBA values in the MenPS and the PRP-T groups were 25.4 (69.7%) and 7.3 (24.3%), respectively, both significantly less than for the MenD groups: P = 0.0001 (P 5 0.01 when comparing MenD 1 pg us. both the 4-and 16-pg MenD groups). One month after the 11-month MenPS vaccination, for both serogroups we observed good SBA GMT values and seroprotection rates at least equal to 90% in the MenD groups (Table 4) . These immune responses appeared to be inversely correlated with the dose and better than that noted for the MenPS group. The same proportion of infants in the MenPS group appeared to be seroprotected (59.3%) against serogroups A and C after this 11-month MenPS vaccination.
DISCUSSION
The objectives of this study were to investigate the safety and immunogenicity in infants in Africa of a new meningococcal conjugate vaccine and t o select a dose for future studies that might allow inclusion of this vaccine in the EPI.
All doses of MenD vaccines were well-tolerated. This is consistent with previous studies indicating that polysaccharide-protein conjugate vaccines, including those directed against N. meningitidis, are moderately reactogenic.10-12 The local reactogenicity profiles of the different doses of MenD vaccines appear comparable with those of MenPS and PRP-T vaccines, although there appeared to be a slight decrease in the local reaction rates when the dose was increased. This may have been the result of either detection bias13 introduced by the sequential approach or a true immunologic effect of the low doses. No difference was observed between the incidences of the systemic reactions observed for the conjugate vaccine and the licensed meningococcal polysaccharide vaccines, with the exception of an apparent increase after three injections of the MenD 16-pg dose, which might be attributable to the greater quantity of diphtheria toxoid.
We used' the 2-pglml cutoff in ELISA measurements and set the limit of detection of the SBA assay (i.e. 1:8) to define seroprotection; however, the seroprotective level of meningococcal antibodies measured by ELISA is not known for certain, but the evidence suggests it to be 1 to 2 pg/ml.14-16 Likewise the functional antibody concentration indicative of protection has not been established7. l4 for the SBA assay used in this study.
After primary immunization MenD elicited ELISA antibody concentrations against serogroup A that were comparable with those obtained after immunization with MenPS, whereas concentrations of antibodies against serogroup C tended to be lower after immunization with the MenD vaccine, especially at the 1-pg dose. The ELISA antibody concentration induced by the 1-pg MenD vaccine was significantly lower than polysaccharide is given at 3 months of age. The relevance of these observations is unknown.
In our study in Niger we observed a decline in SBA against seroSouP c in the h h P S vaccine group from the pre-(62.7) to the post-primary series serum level 
